This Dividend Aristocrat's High Yield Looks Like a Safe Haven

Walgreens Boots Alliance has the fundamentals to back up its rich dividend

Author's Avatar
Nov 29, 2022
Summary
  • This retail pharmacy and health care giant has made several acquisitions that should push up its revenue and earnings.
  • It has been profitable every year for the past decade, but was stung during the early months of the Covid-19 epidemic.
  • The company has a high dividend because its price has been declining for seven years.
Article's Main Image

Investors shopping for income often begin by asking if a dividend, and particularly a high one, is sustainable. It’s a logical and important question every investor should ask.

One form of assurance comes from Dividend Aristocrats. A Dividend Aristocrat is a company in the S&P 500 index that has increased its dividend every year for at least 25 consecutive years, showing consistency and dedication to shareholders.

Walgreens Boots Alliance Inc. (WBA, Financial) is one of those stocks, making it part of the list of just 64 stocks that can call themselves a Dividend Aristocrat as of November 2022.

Not only is it a member of this elite group, but it is also a high-yielding stock. It offers a yield that’s more than double the November S&P 500 average of 1.69%.

About Walgreens Boots Alliance

The original Walgreens Company was founded in 1909. A major transformation occurred in 2014 when Walgreens combined with Boots Alliance. Today, it operates in over 13,000 locations in nine countries. Its major retail and business brands are Walgreens, Boots and Duane Reade. In addition, it has global health and beauty product brands, including No7, NICE!, Soap & Glory, Finest Nutrition, Liz Earle, Botanics, Sleek MakeUP and YourGoodSkin. Based in Deerfield, Illinois, it has a market cap of $35.29 billion and had revenue of $132.703 billion in the fiscal year that ended on Aug. 31, 2022.

Behind its revenue growth lies a series of acquisitions. These three acquisitions were finalized in the past 13 months, showing the company is still working on growing:

  • October 2021: Walgreens increased its investment in Shields, which it calls “a specialty pharmacy integrator and accelerator for hospitals," for $969 million.
  • November 2021: Walgreens bought a majority interest in VillageMD, “a leading, national provider of value-based primary care services," for $5.2 billion. Meanwhile, VillageMD has offered nearly $9 billion to acquire Summit Health-CityMD, which would double VillageMD’s revenue.
  • August 2022: Walgreens acquired a majority interest in CareCentrix, “a leading player in the post-acute and home care management sectors," for $332 million.

One other transaction is worth attention. In May 2022, the company sold 6 million shares of AmerisourceBergen Corporation (ABC, Financial) for $900 million. That reduced its holding to 52,854,867 shares. Following up, it dumped another 10 million shares on Nov. 7, 2022. It has these shares because it previously sold its Alliance Healthcare wholesale business to AmerisourceBergen.

Competition

In the annual report, Walgreens Boots Alliance characterized its competitive environment as follows: “All of our businesses face intense competition from multiple existing and new businesses, some of which are aggressively expanding in markets we serve.”

GuruFocus compares its performance with those of companies such as PetMed Express (PETS, Financial) and Rite Aid (RAD, Financial):

1597371955642728448.png

Fundamentals

Next, let's take a look at the company's fundamentals, which investors can find on its helpful GuruFocus stock summary page.

It has been costly for Walgreens Boots Alliance to make the above-mentioned acquisitions, despite the sale of Alliance Health, which has negatively impacted its financial strength. At the close of its latest fiscal year, on Aug. 31, it had cash, cash equivalents and marketable securities of $2.472 billion. On the other side of the ledger, it had short- and long-term debt of $11.65 billion. While the interest coverage ratio is lower than many would like, it does have a high Piotroski F-Score and safe Altman Z-Score.

The profitability rank is better. Its operating and net margins are still positive but are otherwise terrible. The gross margin is well below average for the health care providers and services industry. However, there’s positive news in seeing the company has been profitable every year in the past decade.

The growth rank is in the middle of the pack. Walgreens Boots Alliance is better than average for revenue, Ebitda and earnings per share without non-recurring items growth rates. Here’s how the earnings per share has grown over the past 10 years:

1597377330332925952.png

After being walloped in the early months of Covid-19, the company has since recovered.

As the following 10-year chart shows, Walgreens Boots Alliance is on a long-term decline, a condition that began back in 2015:

1597428163925868544.png

Perhaps the slide in the share price reflects the company’s highly unpredictable earnings, growing debt or failure to show significant enough growth to justify the acquisitions.

The price-earnings ratio is low at 8.16. The GF Value chart considers the company to be modestly undervalued.

1597642771886342144.png

Dividend and share repurchases

Thanks to that long-suffering share price, the dividend has become attractive:

1597443980679806976.png

The company is a Dividend Aristocrat, with 46 consecutive years of dividend increases according to Dividend.com. For several years now, the dividend yield has been the only thing going for Walgreens Boots Alliance stock. I’m quite sure management will do absolutely everything it can to continue those increases.

What’s more, the dividend is likely safe because the company may have a red-ink balance sheet now, but I have faith that its acquisitions will increase its revenue and earnings power in the coming years.

The company also has been relatively aggressive in buying back its own shares, averaging a reduction of 3.37% per year over the past five years. The board of directors has signaled its confidence by not only making major acquisitions but also by repurchasing its own shares.

What do the gurus think?

Ten of the 12 gurus followed by GuruFocus who owned Walgreens Boots Alliance at the end of the third quarter added to their positions. Jim Simons (Trades, Portfolio) of Renaissance Technologies had the largest holding, with 2,562,000 shares. Overall, institutional investors held 58.51% of shares outstanding, while insiders owned 1.16%.

Conclusion

For income investors, Walgreens Boots Alliance is a company worth considering in my opinion. It has a rich dividend, one that should be sustainable and keep growing. While the company’s other fundamentals may not be inspiring, they are robust enough to maintain shareholder returns.

Disclosures

I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours. Click for the complete disclosure